Deutsche Bank Initiates Coverage on F5 Networks (FFIV) with Hold; Risk/Reward Balanced
FFIV Hot Sheet
Rating Summary:21 Buy, 14 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 9 | New: 35
Deutsche Bank initiates coverage on F5 Networks (Nasdaq: FFIV) with Hold rating and $37 price target.
Deutsche analyst says, "F5 has emerged at the forefront of the application acceleration segment of data networking. We believe this is an important growth area as enterprises move computing resources to the data center and further into the field. We expect continued growth above industry levels for some time. However, at current prices the stock appears to fully reflect its risk/reward potential meriting a Hold rating...Other growth catalysts we see for F5, over the next three years include: integrated applications networking appliances and file virtualization."
To see more analyst ratings on FFIV Click Here.
F5 Networks, Inc. is a provider of application delivery networking products that ensure the security, optimization and availability of applications for any user, anywhere.
Deutsche analyst says, "F5 has emerged at the forefront of the application acceleration segment of data networking. We believe this is an important growth area as enterprises move computing resources to the data center and further into the field. We expect continued growth above industry levels for some time. However, at current prices the stock appears to fully reflect its risk/reward potential meriting a Hold rating...Other growth catalysts we see for F5, over the next three years include: integrated applications networking appliances and file virtualization."
To see more analyst ratings on FFIV Click Here.
F5 Networks, Inc. is a provider of application delivery networking products that ensure the security, optimization and availability of applications for any user, anywhere.
You May Also Be Interested In
- UPDATE: Oppenheimer Starts Jazz Pharmaceuticals (JAZZ) at Outperform
- Compass Point Maintains a 'Neutral' on UDR, Inc. (UDR); Raising PT, But Lowering Estimates
- Credit Suisse Starts Jazz Pharmaceuticals (JAZZ) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Deutsche BankSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
